Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFY study of depemokimab in at-risk type 2 asthma
2025-524463-20-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in asthma and Th2 asthma (Th2) comparing EXDENSUR with Placebo (2 arms). Primary endpoint: Annualized rate of clinically significant exacerbations. Planned start Jul 2026; status: authorised.
02
Drugs
depemokimab
03
Conditions
asthmaTh2 asthma (Th2)
Beyond the preview
Go deeper on 2025-524463-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524463-20-00.